The biotechnology sector has boomed since the recession, providing substantial returns for investors in specialist funds exposed to this area.
Dotcom bubble 2.0?
Dr. Daniel Koller, head of management team, BB Biotech
Investors are showing increasing willingness to pay for R&D pipelines in biotech, explains AXA Framlington's Linden Thomson.
What’s gone wrong with global funds?
Is it worth accessing medical tech stocks via crowdfunding?
Healthcare will see ‘once-in-a-lifetime’ structural shift
The biologic drug boom
Biotech's big trends
Biotech off the beaten track
The biotech sector has stumbled in recent months as investors have moved to take profits on the industry's boom. Daniel Koller, manager of the BB Biotech fund, outlines the new breed of drugs set to push the sector higher.
Google shares moved sharply lower in after-hours trading following a disappointing update, with the negative sentiment that has blighted the sector showing no sign of abating.
The Nasdaq index suffered its worst day since 2011 yesterday, dropping over 3% as investors continued to switch out of technology and biotechnology holdings.
Biotech, digital communications and clean energy have been the three best performing themes in Pictet's Global Megatrends Selection fund this year.
Polar Capital has launched a global biotechnology fund for recent hire David Pinniger, as it seeks to build on its formidable reputation in the space.
A tumultuous June may have taken the edge off many of the sizeable gains made by funds in the first half of 2013, but it was not enough to derail performance completely.
ON SPECIALIST MARKETS
AXA Investment Managers is to hand its Health and Biotech funds to Mark Hargraves and Bruno Grandsard on a temporary basis.
AXA Framlington is to hand Deane Donnigan's Biotech fund to Gemma Game following her shock departure.
IBT's David Pinniger explains how the UK Budget has enhanced the investment story behind biotechnology.
IBT's David Pinniger explains why investors looking for growth should consider the biotech space.